U.S. Professional Services Stock News

NasdaqGS:BMRN
NasdaqGS:BMRNBiotechs

BioMarin Trial Setback Puts Rare Disease Pipeline And Valuation In Focus

BioMarin Pharmaceutical (NasdaqGS:BMRN) reported that BMN 401 missed one of two co-primary endpoints in the Phase 3 ENERGY 3 trial for ENPP1 deficiency. The therapy did not show improvement in skeletal health or key secondary outcomes, raising questions about its regulatory and commercial outlook. The result affects BioMarin's rare disease pipeline at a time when the company is working to broaden its revenue base beyond existing treatments. For investors watching rare disease drug...
NYSE:JOBY
NYSE:JOBYAirlines

Institutional Backing Builds As Joby Nears Commercial Air Taxi Launch

Cathie Wood's ARK Invest and Ken Griffin have recently added to their positions in Joby Aviation (NYSE:JOBY). The increased holdings come ahead of Joby's planned launch of commercial air taxi services. These investments arrive as Joby reports progress on key FAA certification steps and commercial partnerships. The fresh backing contrasts Joby with competitor Archer Aviation and highlights changing market sentiment toward air taxis. Joby Aviation, trading under NYSE:JOBY, is working on...
NYSE:DAC
NYSE:DACShipping

Is It Too Late To Consider Danaos (DAC) After Its 7x Five Year Surge?

Wondering if Danaos at around US$129.81 is still offering value, or if most of the opportunity is already priced in? This article walks through the key signals to help you frame that question clearly. The stock has been relatively active, with the share price down about 2.3% over the past week, up 10.2% over 30 days, up 36.3% year to date, and showing a 58.3% return over the last year, alongside very large multi year gains of more than 7x over five years. These swings in the share price have...
NasdaqGS:IBRX
NasdaqGS:IBRXBiotechs

ImmunityBio’s Anktiva sBLA Review Puts Bladder Cancer Thesis To Test

ImmunityBio (NasdaqGS:IBRX) received FDA acceptance for review of its supplemental Biologics License Application for ANKTIVA plus BCG in BCG-unresponsive non-muscle invasive bladder cancer with papillary disease. The company also released new comparison data indicating improved efficacy and safety of ANKTIVA plus BCG versus other approved bladder cancer therapies, presented at a major medical meeting. These developments relate to a potential expansion of ANKTIVA's approved use and could...
NasdaqGS:RNW
NasdaqGS:RNWRenewable Energy

ReNew Energy Global (RNW) Margin Improvement Tests Bullish Earnings Narratives

ReNew Energy Global (NasdaqGS:RNW) has just wrapped up FY 2026 with fourth quarter revenue of ₹31.8b and basic EPS of ₹2.13, while trailing twelve month EPS stands at ₹28.56 on revenue of ₹132.2b and net income of ₹10.4b. Over the past few quarters, revenue has ranged from ₹25.1b to ₹39.0b with quarterly EPS swinging between a loss of ₹0.54 and a gain of ₹14.14. This gives investors a clear view of how earnings power has tracked alongside top line performance. With trailing net margins higher...
NYSE:NBHC
NYSE:NBHCBanks

How ESOP Share Registration and Dividend Commitment At National Bank Holdings (NBHC) Has Changed Its Investment Story

In May 2026, National Bank Holdings Corporation filed a US$40.88 million shelf registration for 1,000,000 Class A common shares related to its ESOP and earlier affirmed a quarterly dividend of US$0.32 per share payable on June 15, 2026. These capital and dividend moves come as a recent analyst report criticized the bank’s below-sector revenue growth and flat earnings per share over five years, raising fresh questions about its capital generation and valuation framework. We’ll now examine how...
NYSE:CWEN.A
NYSE:CWEN.ARenewable Energy

Should Clearway’s Legal Transition and Widening Net Losses Shape Its Capital Allocation Story (CWEN.A)?

Clearway Energy, Inc. recently announced that longtime Executive Vice President, General Counsel and Corporate Secretary Kevin P. Malcarney will retire effective June 1, 2026, with former company deputy Michael A. Brown returning to succeed him after serving in senior legal roles at The New York Times Company. The leadership change arrives soon after Clearway reported first-quarter 2026 results showing sales rising to US$354 million while net loss widened to US$163 million, drawing fresh...
NYSE:APG
NYSE:APGConstruction

Is APi Group (APG) Still Attractive After Recent Pullback And Strong Multi‑Year Gains

Wondering whether APi Group’s current share price lines up with its underlying worth, or if the recent run has left it looking stretched or still reasonable. The stock closed at US$41.14, with returns of 5.6% year to date and 34.4% over the past year, even though the price has fallen 4.7% over the last week and 12.0% over the last month. Recent attention around APi Group has focused on its longer term share price performance, including a 3 year return of 168.3% and a 5 year return of 201.0%...
NYSE:GRNT
NYSE:GRNTOil and Gas

Undervalued Small Caps With Insider Buying To Enhance Your Portfolio

The United States market has experienced a slight dip of 1.0% over the past week, yet it remains robust with a 23% increase over the past year and earnings projected to grow by 17% annually. In this context, identifying small-cap stocks that are perceived as undervalued and have insider buying activity can be an intriguing strategy for investors seeking potential opportunities amidst fluctuating market conditions.
NYSE:SGHC
NYSE:SGHCHospitality

Agilysys And Two Other Stocks Priced Below Estimated Value

Over the last 7 days, the United States market has experienced a slight decline of 1.0%, yet it remains up by an impressive 23% over the past year, with earnings anticipated to grow by 17% annually. In this context, identifying undervalued stocks like Agilysys and others can be an effective strategy for investors seeking opportunities that are priced below their estimated value in a fluctuating market environment.
NYSE:ALIT
NYSE:ALITProfessional Services

3 Penny Stocks With Market Caps Under $500M And Promising Growth

Over the last 7 days, the United States market has dropped by 1.0%, but it remains up 23% over the past year, with earnings forecasted to grow by 17% annually. In such a dynamic landscape, identifying stocks that combine value and growth potential is key, especially when considering smaller or younger companies often referred to as penny stocks. Though the term may seem outdated, these investments can still offer significant opportunities for those looking to discover under-the-radar...
NasdaqGS:SPFI
NasdaqGS:SPFIBanks

Undiscovered Gems in the US Market for May 2026

Over the last 7 days, the United States market has experienced a slight decline of 1.0%, yet it remains robust with a 23% increase over the past year and an anticipated annual earnings growth of 17%. In this dynamic environment, identifying stocks that are not only resilient but also poised for growth can be key to uncovering hidden opportunities in the market.
NYSE:NPK
NYSE:NPKAerospace & Defense

Did Rising Q1 2026 Sales but Weaker Margins Just Shift National Presto Industries' (NPK) Investment Narrative?

In the first quarter of 2026, National Presto Industries, Inc. reported sales of US$118.65 million, up from US$103.64 million a year earlier, while net income declined to US$6.63 million and basic earnings per share from continuing operations fell to US$0.93 from US$1.07. This combination of higher revenue but lower profitability highlights rising costs or margin pressure as a key theme in the company’s recent performance. Against this backdrop of revenue growth but softer earnings, we’ll...